Please visit answersincme.com/BXW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Katarzyna J. Jerzak, MD, MSc, FRCPC. In this activity, an expert in medical oncology reviews the optimal use of CDK4/6 inhibitors for the treatment of hormone receptor (HR)–positive/HER2-negative early and metastatic breast cancer based on the latest guidelines and long-term evidence. Upon completion of this activity, participants should be better able to: Define patient eligibility for CDK4/6 inhibitor therapy in hormone receptor (HR)–positive/HER2-negative early and metastatic breast cancer per the Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance recommendations; Evaluate long-term clinical evidence supporting CDK4/6 inhibitors with endocrine therapy in HR-positive/HER2-negative early and metastatic breast cancer; and Apply evidence-based, patient-centered strategies to optimize long-term management of HR-positive/HER2-negative early and metastatic breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related